[1]唐毅 唐艺金 黄培 杨小燕 张翼 彭建强 郑昭芬 王银珍.人附睾蛋白4对扩张型心肌病患者短期预后评估的价值[J].心血管病学进展,2021,(11):1052-1056.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
　TANG Yi,TANG Yijin,HANG Pei,et al.The Value of Human Epididymal Protein 4 in Assessment of Short-Term Prognosis of Patients with Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(11):1052-1056.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
点击复制

人附睾蛋白4对扩张型心肌病患者短期预后评估的价值()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年11期
页码:
1052-1056
栏目:
论著
出版日期:
2021-11-25

文章信息/Info

Title:
The Value of Human Epididymal Protein 4 in Assessment of Short-Term Prognosis of Patients with Dilated Cardiomyopathy
文章编号:
202106093
作者:
唐毅1 唐艺金2 黄培2 杨小燕2 张翼1 彭建强1 郑昭芬1 王银珍2
(1.湖南省人民医院(湖南师范大学附属第一医院)
Author(s):
TANG Yi 1 ; TANG Yijin2; HANG Pei2; YANG Xiaoyan2; ZHANG Yi1; PENG Jianqiang1; ZHENG Zhaofen1; WANG Yinzhen2
(1. Department of Cardiology, Hunan Provincial People’s Hospital(The First Affiliated Hospital of Hunan Normal University),Changsha 410005,Hunan,China; 2. Department of Cardiology,The First Affiliated Hospital of Hunan Normal University(Hunan Provincial People’s Hospital),Changsha 410005,Hunan,China)
关键词:
人附睾蛋白4; 扩张型心肌病; 预后
Keywords:
Human epididymal protein 4; Dilated cardiomyopathy; Prognosis
DOI:
10.16806/j.cnki.issn.1004-3934.2021.11.000
摘要:
目的 探讨人附睾蛋白4（HE4）对扩张型心肌病（DCM）患者短期预后评估的价值。 方法 收集2019年2月—2020年12月就诊于湖南省人民医院心 血管内科的DCM患者的基线临床资料，并使用化学发光法检测其血清HE4水平。在患者出院后进行定期随访并记录终点事件，终点事件包括因心力衰竭再住院和心血管死亡。采用Kaplan-Meier曲线、单因素和多因素Cox比例风险回归模型进行生存分析。结果 纳入研究的100例DCM患者的 中位随访时间为6.65个月（2.28～12.88个月），其中有44例发生终点事件。Cox多因素回归分析结果表明HE4[χ2=6.854，HR=1.002（95% CI 1.001 ～1.004），P=0.009]和年龄[χ2=8.938，HR=1.039（95% CI 1.013～1.066），P=0.013（0.003？）]是DCM患者发生终点事件的独立预测指标，且HE4水平＞66.8 pmol/L的DCM患者发生终点事件的风险明显高于HE4水平≤66.8 pmol/L的DCM患者（Log-rank test:χ2=6.560，P=0.010），校正了年龄、性别、估算的肾小球滤过率及心房颤动后的HR为2.164（95% CI 1.034 ～4.530），差异有统计学意义（P=0.040）。结论 HE4是预测DCM患者短期内发生心力衰竭再住院和心血管死亡事件的一个重要指标。
Abstract:
Objective To investigate the value of human epididymal protein 4(HE4) in assessment of short-term prognosis for patients with dilated cardiomyopathy(DCM). Methods Baseline clinical data of DCM patients admitted in the department of cardiology of Hunan Provincial People’s Hospital from February 2019 to December 2020 were collected ,and the serum HE4 level was detected by chemiluminescence method. The patients were followed up 基金项目：国家自然科学基金(81800056)；湖南省社会发展领域重点研发项目(2019SK2021)；湖南省科技创新重点工程(2020SK1013)；湖南省临床医疗技术创新引导项目(2020SK50922)；湖南省自然科学基金(2021JJ40294)通信作者：王银珍，E-mail:1186212245@qq.com regularly after discharge to record the endpoint events,and the endpoint events were defined as readmission due to heart failure and cardiovascular death. Kaplan Meier curve,univariate and multivariate Cox proportional hazard regression models were used for analyzing survival. Results The 100 DCM patients included in the study had a median follow-up duration of 6.65 months(2.28～12.88 months),and among these patients,44(44%) had endpoint events. Cox multivariate regression analysis showed that HE4[χ2=6.854,HR=1.002（95% CI 1.001～1.004), P=0.009] and age[χ2=8.938,HR=1.039(95% CI 1.013～1.066), P=0.003] were independent predictors of endpoint events in DCM patients. DCM patients with HE4 level>66.8 pmol/L had significantly higher risk of endpoint events than DCM patients with HE4 level≤66.8 pmol/L(log rank test:χ2=6.560, P=0.010). After adjusting for age,sex,estimated glomerular filtration rate and atrial fibrillation,the HR was 2.164 (95% CI 1.034~4.530), and the difference was statistically significant(P=0.040). Conclusion HE4 is an important indicator for predicting heart failure rehospitalization and cardiovascular death in patients with DCM in the short term.

参考文献/References:

[1] Schultheiss HP,Fairweather D,Caforio ALP,et al. Dilated cardiomyopathy[J]. Nat Rev Dis Primers,2019,5(1):32-51.

[2] Pinto YM,Elliott PM,Arbustini E,et al. Proposal for a revised definition of dilated cardiomyopathy,hypokinetic non-dilated cardiomyopathy,and its implications for clinical practice:a position statement of the ESC working group on myocardial and pericardial diseases[J]. Eur Heart J,2016 ,37(23):1850-1858.

[3] H?nselmann A,Veltmann C,Bauersachs J,et al. Dilated cardiomyopathies and non-compaction cardiomyopathy[J]. Herz,2 020,45(3):212-220.

[4]Bingle CD,Vyakarnam A. Novel innate immune functions of the whey acidic protein family[J]. Trends Immunol,2008,29(9):444-453.

[5] LeBleu VS,Teng Y,O’connell JT,et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis[J]. Nat Med,201 3,19(2):227-231.

[6] Piek A,Du W,Boer R,et al. Novel heart failure biomarkers:why do we fail to exploit their potential?[J]. Crit Rev Clin Lab Sci,2018,55(4):246-263.

[7] de Boer RA,Cao Q,Postmus D,et al. The WAP four-disulfide core domain protein HE4:a novel biomarker for heart failure[J]. JACC Heart Fail,2013,1(2):164-169.

[8] Piek A,Meijers WC,Schroten NF,et al. HE4 serum levels are associated with heart failure severity in patients with chronic heart failure[J]. J Card Fail,201 7,23(1):12-19.

[9] Sp?nig S,Kellermann K,Dieterlen MT,et al. The ubiquitin proteasome system in ischemic and dilated cardiomyopathy[J]. Int J Mol Sci,2019,20(24):6354

[10] 杨杰孚,廖玉华,袁璟,等. 中国扩张型心肌病诊断和治疗指南[J]. 临床心血管病杂志,2018,34 (5):421-434.

[11] Benjamin EJ,Virani SS,Callaway CW,et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association[J]. Circulation,2018 ,137(12):e67-e492.

[12] Cabac-Pogorevici I,Muk B,Rustamova Y,et al. Pathophysiological insights,diagnostic management and the roles of revascularisation and device treatment. Gaps and dilemmas in the era of advanced technology[J]. Eur J Heart Fail,2020 ,22(5):789-799.

[13]Briceno N,Schuster A,Lumley M,et al. Ischaemic cardiomyopathy:pathophysiology,assessment and the role of revascularisation[J]. Heart,201 6,102(5):397-406.

[14]Espiau Romera A,Cuesta Guardiola T,Benito Vielba M,et al. HE4 tumor marker as a predictive factor for lymphatic metastasis in endometrial cancer[J]. Int J Gynecol Obstetr,2020,149(3):265-268.

[15]Hertlein L,Stieber P,Kirschenhofer A,et al. Human epididymis protein 4(HE4) in benign and malignant diseases[J]. Clin Chem Lab Med ,2012,50(12):2181-2188.

[16] Sinagra G,Merlo M,Pinamonti B. Dilated cardiomyopathy:from genetics to clinical management[OL]. Cham(CH):Springer,2019.PMID:32091676.

[17] Wan J,Wang Y,Cai G,et al. Elevated serum concentrations of HE4 as a novel biomarker of disease severity and renal fibrosis in kidney disease[J] . Oncotarget,20 16,7(42):67748-67759.

相似文献/References:

[1]张颖雪,赵新湘,孙勇.心脏磁共振成像技术在扩张型心肌病中的应用及研究进展[J].心血管病学进展,2016,(1):74.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.019]
　ZHANG Yingxue,ZHAO Xinxiang,SUN Yong.Application and Research Progress of Cardiac Magnetic Resonance Imaging in Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(11):74.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.019]
[2]吴琼,杨爱玲,周端,等.扩张型心肌病左室逆重构的研究进展[J].心血管病学进展,2019,(6):885.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.012]
　WU Qiong,YANG Ailing,ZHOU Duan,et al.Left Ventricular Reverse Remodeling in Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(11):885.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.012]
[3]刘超 曲杰 王明娟 徐倩 范彦芳 周晓慧 单伟超.肺动脉高压对扩张型心肌病预后的影响[J].心血管病学进展,2020,(4):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
　LIU ChaoQU JieWANG MingjuanXU QianFAN YanfangZHOU XiaohuiSAN Weichao.The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(11):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
[4]梁科研 杨芳 褚静洁.四维超声心动图评价扩张型心肌病右心室整体收缩功能及其临床意义[J].心血管病学进展,2020,(5):547.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.025]
　LIANG Keyan,YANG Fang,CHU Jingjie.Four-dimensional Echocardiography for Evaluation of Right Ventricular Systolic Function in Dilated Cardiomyopathy and Its Clinical Significance[J].Advances in Cardiovascular Diseases,2020,(11):547.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.025]
[5]宋元秀 崔鸣.线粒体动力学异常与相关心血管疾病[J].心血管病学进展,2021,(2):162.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
　SONG Yuanxiu,CUI Ming.Correlation Between Mitochondrial Dynamics and Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2021,(11):162.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]

更新日期/Last Update: 2021-12-06